CRISPR Therapeutics AG $CRSP Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 2,346.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 230,305 shares of the company’s stock after acquiring an additional 220,892 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in CRISPR Therapeutics were worth $12,077,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in shares of CRISPR Therapeutics by 98.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 593,416 shares of the company’s stock worth $38,459,000 after acquiring an additional 294,222 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its holdings in shares of CRISPR Therapeutics by 44.7% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 283,111 shares of the company’s stock worth $18,348,000 after acquiring an additional 87,509 shares during the period. O Neil Global Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth about $10,934,000. UBS Group AG increased its holdings in shares of CRISPR Therapeutics by 7.7% in the 4th quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock worth $132,366,000 after acquiring an additional 180,580 shares during the period. Finally, SR One Capital Management LP increased its holdings in shares of CRISPR Therapeutics by 94.4% in the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock worth $132,132,000 after acquiring an additional 989,812 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $49.90 on Friday. The company’s 50 day moving average price is $50.87 and its 200 day moving average price is $53.28. CRISPR Therapeutics AG has a 52 week low of $35.38 and a 52 week high of $78.48. The company has a market capitalization of $4.81 billion, a PE ratio of -8.02 and a beta of 1.74. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The company had revenue of $1.46 million for the quarter. Research analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on CRSP. Evercore restated an “outperform” rating and issued a $76.00 target price on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Bank of America cut their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Sanford C. Bernstein upped their target price on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $65.47.

Insider Activity at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,150 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $152,019.00. Following the transaction, the insider directly owned 13,143 shares of the company’s stock, valued at approximately $634,281.18. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 10,349 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total transaction of $499,442.74. Following the completion of the sale, the chief executive officer owned 245,834 shares of the company’s stock, valued at $11,863,948.84. This trade represents a 4.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 42,749 shares of company stock valued at $2,100,723. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.